Objective:
To evaluate the long-term efficacy and safety of the port delivery system (PDS) with ranibizumab (Susvimo) in patients with neovascular age-related macular degeneration (nAMD).
Key Findings:
- Sustained vision outcomes with about half of patients retaining 20/40 vision or better after 5 years.
- Mean best-corrected visual acuity (BCVA) declined minimally (7 letters) compared to greater declines in other studies (12-17 letters).
- Stable retinal thickness observed in both groups.
- 95%+ of patients managed to go 6 months between PDS refills without needing rescue treatment.
- Low endophthalmitis rate of 2.6%, with improved outcomes following surgical updates.
Interpretation:
The PDS with ranibizumab offers a durable treatment option for nAMD, demonstrating effective disease control and reduced treatment burden over 5 years.
Limitations:
- The study cohort may not fully represent the broader nAMD population.
- Long-term outcomes beyond 5 years are still unknown as the study is ongoing.
Conclusion:
The Portal study indicates that continuous maintenance therapy with the PDS can improve patient outcomes in nAMD while minimizing treatment frequency.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.